FDG PET/CT in monitoring treatment of retroperitoneal fibrosis

Yilmaz, S.; Tan, Y.; Ozhan, M.; Halac, M.; Asa, S.; Sonmezoglu, K.

doi:10.1016/j.remn.2012.04.001

FDG PET/CT in monitoring treatment of retroperitoneal fibrosis

Yilmaz S., Tan Y. Z., Ozhan M., Halac M., Asa S., Sonmezoglu K.

REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, vol.31, no.6, pp.338-339, 2012 (SCI-Expanded)

Publication Type: Article / Article
Volume: 31 Issue: 6
Publication Date: 2012
Doi Number: 10.1016/j.remn.2012.04.001
Journal Name: REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.338-339
Istanbul University Affiliated: Yes

Abstract

Retroperitoneal fibrosis is an uncommon disease characterized by inflammatory fibrosis typically surrounding abdominal aorta and iliac arteries. The glucose analogue F18-fluorodeoxyglucose can be used to image inflammatory cell activity non-invasively by PET. In this report we investigated the usefulness of the FDG PET/CT in the disease activity and therapy response evaluation of retroperitoneal fibrosis. (C) 2012 Elsevier Espana, S.L. and SEMNIM. All rights reserved.